Bioequivalence Study of Ranolazine Extended-release Tablets in Healthy Chinese Subjects
Status:
COMPLETED
Trial end date:
2020-12-21
Target enrollment:
Participant gender:
Summary
The present study was conducted with the objective of comparing the bioequivalence and safety of a single dose of ranolazine extended-release tablets (Test product) manufactured by Haisco Pharmaceutical Group Co., Ltd. with those of the reference product (Ranexa, Gilead Sciences, Inc.) in Chinese healthy subjects under fasting and fed conditions